Contact
searchSearch
HMP Global
Login

Kidney Cancer

News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
From Oncology
News
Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective...
03/11/2024
Oncology
From Oncology
News
FDA Approves Belzutifan For Advanced Kidney Cancer
03/04/2024

Emry Lloyd

Emry Lloyd
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan,...
03/04/2024
Journal of Clinical Pathways
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Dr Rana McKay, medical oncologist at the University of California in San Diego.
Videos
Characterization of FOLH1 Expression in Renal Cell Carcinoma
04/11/2023
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate...
04/11/2023
Journal of Clinical Pathways
News
Interactive Data Visualization Tool Facilitates Shared Decision-Making in Kidney Cancer
09/21/2021
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an...
09/21/2021
Journal of Clinical Pathways
Quiz
Quiz: Disparities in Treatment Decision-Making for Kidney Cancer
09/02/2021
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are...
09/02/2021
Journal of Clinical Pathways
News
Clinical and Economic Impact of Early vs Delayed Progression After First-Line TKIs in Patients With Metastatic RCC
08/30/2021
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after...
08/30/2021
Journal of Clinical Pathways
News
Disparities in Treatment Decision-Making for Patients With Kidney Cancer
08/11/2021
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex,...
08/11/2021
Journal of Clinical Pathways
News
Real-World Patterns and Predictors of Oral Anticancer Agent Use Among Patients With Metastatic RCC
07/29/2021
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral...
07/29/2021
Journal of Clinical Pathways

Expert Insights

Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Dr Rana McKay, medical oncologist at the University of California in San Diego.
Videos
Characterization of FOLH1 Expression in Renal Cell Carcinoma
04/11/2023
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate...
04/11/2023
Journal of Clinical Pathways
Videos
Real-World Use of Cabozantinib Plus Direct Oral Anticoagulants in RCC
04/21/2021
04/21/2021
Journal of Clinical Pathways
Videos
Patterns and Predictors of Oral Anticancer Agent Use for Metastatic RCC
03/18/2021
03/18/2021
Journal of Clinical Pathways
Videos
Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC
03/18/2021
03/18/2021
Journal of Clinical Pathways
Videos
Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC
02/25/2021
02/25/2021
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
  Key Clinical Summary Dual-targeting CAR T-cell therapy shows promise: Findings from the phase 2 ZUMA-14 trial suggest that combining axicabtagene ciloleucel (axi-cel) with rituximab may improve response durability by...
  Key Clinical Summary Dual-targeting CAR T-cell therapy shows promise: Findings from the phase 2 ZUMA-14 trial suggest that combining axicabtagene ciloleucel (axi-cel) with rituximab may improve response durability by...
  Key Clinical...
07/06/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration: Part 2
06/17/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores...
06/17/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration
06/17/2026
Kishen Patel, PharmD
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel,...
06/17/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Interview
Cardiopulmonary Comorbidities and CRS Risk After CAR T-Cell Therapy in DLBCL: Insights From Real-World Data
06/11/2026
Heidi Cho, MD
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that...
06/11/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Diffuse Large B-Cell Lymphoma, DLBCL
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis
05/26/2026
Nishanth Thalambedu, MD
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part II
05/26/2026
Mark A. Socinski, MD
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of...
05/26/2026
Journal of Clinical Pathways

Newsfeed

News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
News
Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective...
03/11/2024
Oncology
News
FDA Approves Belzutifan For Advanced Kidney Cancer
03/04/2024

Emry Lloyd

Emry Lloyd
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan,...
03/04/2024
Journal of Clinical Pathways
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
News
Interactive Data Visualization Tool Facilitates Shared Decision-Making in Kidney Cancer
09/21/2021
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an...
09/21/2021
Journal of Clinical Pathways
News
Clinical and Economic Impact of Early vs Delayed Progression After First-Line TKIs in Patients With Metastatic RCC
08/30/2021
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after...
08/30/2021
Journal of Clinical Pathways
News
Disparities in Treatment Decision-Making for Patients With Kidney Cancer
08/11/2021
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex,...
08/11/2021
Journal of Clinical Pathways
News
Real-World Patterns and Predictors of Oral Anticancer Agent Use Among Patients With Metastatic RCC
07/29/2021
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral...
07/29/2021
Journal of Clinical Pathways
Conference Coverage
Nivolumab Plus Ipilimumab Cost-Effective for Intermediate or Poor Risk RCC
10/08/2020
10/08/2020
Journal of Clinical Pathways
News
Selinexor Plus Ruxolitinib Demonstrates Improved Efficacy in Patients With Myelofibrosis
07/22/2026
Rebecca Amrick
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib...
07/22/2026
Journal of Clinical Pathways
News
Patients With Functional High-Risk MM Could Benefit from Early Receipt of T-Cell Therapy
07/21/2026
Rebecca Amrick
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining...
07/21/2026
Journal of Clinical Pathways
Conference Coverage
Using Real-World Data to Improve HRR Testing Rates Among Patients With mCRPC
07/17/2026
Andy Osterland, PharmD, MS
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS,...
07/17/2026
Journal of Clinical Pathways
News
APP-Led Benign Hematology Consults Improve Access in Community Oncology, Study Finds
07/16/2026
Grace Taylor, MS, MA
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The...
07/16/2026
Journal of Clinical Pathways
News
Evolutions in Frontline Treatment Patterns for Newly Diagnosed MM
07/15/2026
Rebecca Amrick
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a...
07/15/2026
Journal of Clinical Pathways
News
JAK Inhibitors Demonstrate Improved Efficacy but Worse Toxicity in Myelofibrosis
07/13/2026
Rebecca Amrick
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase...
07/13/2026
Journal of Clinical Pathways
Jessica Paulus Headshot
Conference Coverage
Distress Thermometer Scores Highlight Association Between Psychosocial Distress and Survival Outcomes for Cancer Patients
07/13/2026
Jessica Paulus, ScD
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses...
07/13/2026
Journal of Clinical Pathways
News
Circulating Tumor DNA Could Improve Minimal Residual Disease Detection for Ovarian Cancer
06/26/2026
Rebecca Amrick
Circulating tumor DNA shows promise as a non-invasive alternative to second look laparoscopy at detecting minimal residual disease detection and predicting survival outcomes for patients with ovarian cancer.
Circulating tumor DNA shows promise as a non-invasive alternative to second look laparoscopy at detecting minimal residual disease detection and predicting survival outcomes for patients with ovarian cancer.
Circulating tumor DNA shows...
06/26/2026
Journal of Clinical Pathways
News
IOTA ADNEX Model Outperforms Current Ovarian Cancer Triage Standard
06/23/2026
Hannah Musick
The International Ovarian Tumour Analysis Assessment of Different Neoplasias (IOTA ADNEX) ultrasound model more than doubled ovarian cancer detection sensitivity compared with the current Risk of Malignancy Index standard, supporting its...
The International Ovarian Tumour Analysis Assessment of Different Neoplasias (IOTA ADNEX) ultrasound model more than doubled ovarian cancer detection sensitivity compared with the current Risk of Malignancy Index standard, supporting its...
The International Ovarian Tumour...
06/23/2026
Journal of Clinical Pathways
News
CAR T Therapy Demonstrates Improved Efficacy but Increased Toxicity in Patients With Relapsed or Refractory MM
06/22/2026
Rebecca Amrick
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR)...
06/22/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Disparities in Treatment Decision-Making for Kidney Cancer
09/02/2021
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are...
09/02/2021
Journal of Clinical Pathways
Quiz
Quiz: Oral Anticancer Agent Use for Metastatic RCC
05/05/2021
05/05/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use